These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 38131129)

  • 1. Identification of risk factors associated with acute kidney injury in patients taking sodium-glucose cotransporter-2 inhibitors.
    Schumacher C; Chorpash A; Bolch C; Eagan K; Nimer S; Van Dril E
    Pharmacotherapy; 2024 Mar; 44(3):249-257. PubMed ID: 38131129
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Acute Kidney Injury Events in Patients With Type 2 Diabetes Using SGLT2 Inhibitors Versus Other Glucose-Lowering Drugs: A Retrospective Cohort Study.
    Rampersad C; Kraut E; Whitlock RH; Komenda P; Woo V; Rigatto C; Tangri N
    Am J Kidney Dis; 2020 Oct; 76(4):471-479.e1. PubMed ID: 32464161
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Use of sodium-glucose cotransporter-2 inhibitors and risk of acute kidney injury in older adults with diabetes: a population-based cohort study.
    Iskander C; Cherney DZ; Clemens KK; Dixon SN; Harel Z; Jeyakumar N; McArthur E; Muanda FT; Parikh CR; Paterson JM; Tangri N; Udell JA; Wald R; Garg AX
    CMAJ; 2020 Apr; 192(14):E351-E360. PubMed ID: 32392523
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Characterization of Risk Factors for Genitourinary Infections with Sodium-Glucose Cotransporter-2 Inhibitors.
    Benjamin T; Schumacher C
    Pharmacotherapy; 2020 Oct; 40(10):1002-1011. PubMed ID: 32866995
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Acute kidney injury following SGLT2 inhibitors among diabetic patients: a pharmacovigilance study.
    Chen G; Li X; Cui Q; Zhou Y; Zhao B; Mei D; Xuemei
    Int Urol Nephrol; 2022 Nov; 54(11):2949-2957. PubMed ID: 35579781
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Acute Kidney Injury in Patients on SGLT2 Inhibitors: A Propensity-Matched Analysis.
    Nadkarni GN; Ferrandino R; Chang A; Surapaneni A; Chauhan K; Poojary P; Saha A; Ferket B; Grams ME; Coca SG
    Diabetes Care; 2017 Nov; 40(11):1479-1485. PubMed ID: 28827404
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The SGLT2 Inhibitor Empagliflozin Might Be a New Approach for the Prevention of Acute Kidney Injury.
    Chu C; Lu YP; Yin L; Hocher B
    Kidney Blood Press Res; 2019; 44(2):149-157. PubMed ID: 30939483
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Acute renal outcomes with sodium-glucose co-transporter-2 inhibitors: Real-world data analysis.
    Cahn A; Melzer-Cohen C; Pollack R; Chodick G; Shalev V
    Diabetes Obes Metab; 2019 Feb; 21(2):340-348. PubMed ID: 30207040
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Harnessing basic and clinic tools to evaluate SGLT2 inhibitor nephrotoxicity.
    Saly DL; Perazella MA
    Am J Physiol Renal Physiol; 2017 Oct; 313(4):F951-F954. PubMed ID: 28637789
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Acute kidney injury and adverse renal events in patients receiving SGLT2-inhibitors: A systematic review and meta-analysis.
    Menne J; Dumann E; Haller H; Schmidt BMW
    PLoS Med; 2019 Dec; 16(12):e1002983. PubMed ID: 31815931
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prevention and Management of Genital Mycotic Infections in the Setting of Sodium-Glucose Cotransporter 2 Inhibitors.
    Engelhardt K; Ferguson M; Rosselli JL
    Ann Pharmacother; 2021 Apr; 55(4):543-548. PubMed ID: 32808541
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Network Meta-Analysis of Novel Glucose-Lowering Drugs on Risk of Acute Kidney Injury.
    Zhao M; Sun S; Huang Z; Wang T; Tang H
    Clin J Am Soc Nephrol; 2020 Dec; 16(1):70-78. PubMed ID: 33376101
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical Spectrum and Mechanism of Acute Kidney Injury in Patients with Diabetes Mellitus on SGLT-2 Inhibitors.
    Perlman A; Heyman SN; Stokar J; Darmon D; Muszkat M; Szalat A
    Isr Med Assoc J; 2018 Aug; 20(8):513-516. PubMed ID: 30084579
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Acute renal failure with sodium-glucose-cotransporter-2 inhibitors: Analysis of the FDA adverse event report system database.
    Perlman A; Heyman SN; Matok I; Stokar J; Muszkat M; Szalat A
    Nutr Metab Cardiovasc Dis; 2017 Dec; 27(12):1108-1113. PubMed ID: 29174031
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sodium-Glucose Cotransporter-2 Inhibitors and the Risk of Amputation: What Is Currently Known?
    Misher A; Ampuero A; Phan R; Aziz S; Ebong E; Braich J; Dyches K; Southwood R
    Am J Ther; 2020 Mar; 28(1):e96-e110. PubMed ID: 32384319
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparative effectiveness and safety of sodium-glucose cotransporter-2 inhibitors versus metformin in patients with type 2 diabetes: An observational study using data from routine care.
    Fralick M; Schneeweiss S; Redelmeier DA; Razak F; Gomes T; Patorno E
    Diabetes Obes Metab; 2021 Oct; 23(10):2320-2328. PubMed ID: 34169619
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The current role of sodium-glucose cotransporter 2 inhibitors in type 2 diabetes mellitus management.
    Xu B; Li S; Kang B; Zhou J
    Cardiovasc Diabetol; 2022 May; 21(1):83. PubMed ID: 35614469
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Kidney outcomes in patients with diabetes mellitus did not differ between individual sodium-glucose cotransporter-2 inhibitors.
    Suzuki Y; Kaneko H; Okada A; Matsuoka S; Fujiu K; Michihata N; Jo T; Takeda N; Morita H; Node K; Nangaku M; Yasunaga H; Komuro I
    Kidney Int; 2022 Nov; 102(5):1147-1153. PubMed ID: 35961884
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Kidney outcomes associated with use of SGLT2 inhibitors in real-world clinical practice (CVD-REAL 3): a multinational observational cohort study.
    Heerspink HJL; Karasik A; Thuresson M; Melzer-Cohen C; Chodick G; Khunti K; Wilding JPH; Garcia Rodriguez LA; Cea-Soriano L; Kohsaka S; Nicolucci A; Lucisano G; Lin FJ; Wang CY; Wittbrodt E; Fenici P; Kosiborod M
    Lancet Diabetes Endocrinol; 2020 Jan; 8(1):27-35. PubMed ID: 31862149
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Acute kidney injury with sodium-glucose co-transporter-2 inhibitors: A meta-analysis of cardiovascular outcome trials.
    Gilbert RE; Thorpe KE
    Diabetes Obes Metab; 2019 Aug; 21(8):1996-2000. PubMed ID: 31050116
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.